Securities code: Blue Sail Medical Co.Ltd(002382) securities abbreviation: Blue Sail Medical Co.Ltd(002382) Announcement No.: 2022016 bond Code: 128108 bond abbreviation: lanfan convertible bond
Blue Sail Medical Co.Ltd(002382) 2021 annual report summary
1、 Important note: the summary of this annual report comes from the full text of the annual report. In order to fully understand the company's operating results, financial status and future development plan, investors should carefully read the full text of the annual report in the media designated by the CSRC. In addition to the following directors, other directors attended the meeting of the board of directors to consider the annual report in person
Name of director not present in person position of director not present in person reason for not attending the meeting name of the entrusted person
Tips of non-standard audit opinions □ applicable √ not applicable to the profit distribution plan of common stock or the plan of converting accumulation fund into share capital in the reporting period reviewed by the board of directors √ applicable □ not applicable whether to convert accumulation fund into share capital □ yes √ no the company's profit distribution plan of common stock reviewed and approved by the board of directors is: Based on the total share capital registered on the date of equity distribution registration, Distribute cash dividends of 1.00 yuan (including tax) to all shareholders for every 10 shares, and give 0 bonus shares (including tax), and do not use the accumulation fund to increase the share capital. Profit distribution plan for preferred shares adopted by the board of directors during the reporting period □ applicable √ not applicable II. Basic information of the company 1. Company profile
Stock abbreviation Blue Sail Medical Co.Ltd(002382) stock code Blue Sail Medical Co.Ltd(002382)
Shenzhen Stock Exchange
Contact person and contact information secretary of the board of directors securities affairs representative
Name: Zhong Shuqiao, Zhao Min
Office address: Building 5, yard 5, Anding Road, Chaoyang District, Beijing b1106, international center, No. 48, Yinuo Road, Jixia street, Linzi District, Zibo City, Shandong Province, China
Fax 0533787107305337871073
Tel: 05337871008
E-mail [email protected]. [email protected].
2. Introduction to main business or products during the reporting period
(1) Main business of the company
Since 2018, the "a + X" strategy determined by the company has set sail in an all-round way. Relying on the development path of both endogenous and extension, the company has continued to enter a number of carefully selected "low, medium and high value" medical device consumables tracks. Today, the company's "a + X" strategy is basically implemented, and has become a multinational leading medical device enterprise with a complete layout of low-value consumables and high-value consumables. At the end of 2021, the company launched a comprehensive strategic upgrade, redefined "new medical treatment + great health", and accelerated the transformation to high-quality and innovative development. According to the business nature of the subdivided fields, the company divides its business segments into protection division, cardio cerebrovascular division and nursing division. The company has developed into the forefront of the industry in all subdivided fields, and has fully possessed the platform, resources and foundation for high-quality development.
① Protection Division: at present, its main business is the production and sales of medical and protective gloves, including disposable medical gloves, household gloves, etc., which are mainly used in medical inspection and protection, food processing, electronic industry, etc. At present, the company has a full range of medical and protective gloves, the main products are nitrile gloves, PVC gloves, latex gloves and TPE gloves / CPE gloves.
② Cardio cerebrovascular Division: Currently, it is mainly engaged in the R & D, production and sales of cardiac stents and interventional cardiac surgery related instruments. The main products include drug-eluting stents, drug coated stents, balloon catheters, implantation devices for transcatheter aortic valve replacement (TAVR) and other supporting products for interventional cardiac surgery. At present, drug coated balloon (DCB) is undergoing clinical trials. The new generation TAVR products are planned to carry out clinical trials in Europe, Southeast Asia and China in 2022. The products under research also include solutions for total coronary calcification / CTO lesions, transcatheter mitral valve repair and replacement and other projects.
③ Nursing department: at present, its main business is to develop, produce and sell all kinds of emergency rescue products and disposable health protection products mainly medical first-aid bags. The main products include vehicle first-aid kits, medical first-aid kits, family disaster prevention emergency kits and other first-aid kits, reflective vests, masks, medical dressings and so on. Wuhan bikele rescue supplies Co., Ltd. (hereinafter referred to as "Wuhan bikele") makes full use of the resources of the network platform, carries out Wuxi Online Offline Communication Information Technology Co.Ltd(300959) business simultaneously, and actively develops new channels, new markets, new customers and new products. In 2021, Wuhan bikaier will sell more than 10million sets of first-aid kits, nearly 70million masks and more than 1.6 million reflective vests. Wuhan bikele's products are sold to Germany, Britain and other countries around the world. While constantly exploring foreign markets, it actively develops products that meet the needs of the Chinese market.
(2) Industry of the company
① Protection Division
Since 2021, with the strengthening of New Coronavirus pneumonia epidemic prevention and control measures and the accumulation of epidemic prevention experience, the impact of the epidemic on public health and the impact on economic activities has gradually weakened. However, the recent COVID-19 variant of the virus has been called the global alert, and there are many uncertainties in the future development of New Coronavirus. From a more long-term perspective, New Coronavirus has shown a tendency to coexist with human society for a long time. The epidemic has promoted people's attention to safety and health. According to the frost Sullivan report, the global sales volume of disposable protective gloves is expected to increase from 529 billion in 2019 to 1285.1 billion in 2025 (CAGR 15.9%). However, at the same time, the supply of newly built capacity in the global glove industry has also increased significantly in the past two years, basically matching the increase on the demand side. The prices of major glove categories have gradually dropped back to the level before the outbreak of the epidemic, and some varieties even have overcapacity.
Since the outbreak of covid-19 epidemic, not only the demand for medical and protective gloves in various application scenarios around the world has been sharply driven, but also gave birth to a major strategic opportunity for the reconstruction of the global industrial chain. Before the outbreak, about two-thirds of the world's main production capacity of medical and protective gloves was in Southeast Asia and one-third in China; The main production capacity of nitrile gloves, the fastest growing category, is mostly in Southeast Asia. Chinese enterprises benefited from China's effective epidemic prevention and control, resumed production first, and seized market share through rapid expansion of production capacity. In order to seize the market opportunity, the company has successively carried out various project construction in the past two years. In 2021, the company has released more than 20 billion pieces of new production capacity, including nitrile gloves, PVC gloves, latex gloves and other projects, with a cumulative production capacity of about 50 billion pieces, comprehensively improving the company's business scale and industry influence. The company has developed from the champion of single sales category of PVC gloves in the past to the only company with complete categories of four major gloves in the industry.
② Cardiovascular and cerebrovascular business department
In recent years, with the rapid development of China's economy and the continuous improvement of residents' living standards, the level and coverage of basic medical security have also been improved accordingly. China's medical device market has developed rapidly. The average annual growth rate of China's medical device market is predicted to be 63.8 billion yuan in 2016, far exceeding that of China's medical device market of 63.1 billion yuan in 2019. On December 28, 2021, the "14th five year plan" for the development of medical equipment industry was released, which is the first industrial development plan in the field of medical equipment at the national level, which will be conducive to the overall future development of the medical device industry. With the technological progress of Chinese medical device enterprises and the maturity of supporting industrial chain, the intensification of population aging, the improvement of residents' health awareness and the deepening of government support policies, the continuous expansion of medical device market is promoted. The newly revised regulations on the supervision and administration of medical devices will come into force on June 1, 2021, bringing the innovation of medical devices into the focus of development, giving priority to the review and approval of Innovation Medical Management Co.Ltd(002173) devices, supporting the clinical promotion and use of Innovation Medical Management Co.Ltd(002173) devices, and promoting the high-quality development of the medical device industry. At the same time, according to the implementation of the national pilot reform of high-value consumables management and the release of the guiding opinions on the centralized procurement and use of high-value medical consumables, it is expected that the policy of centralized procurement of high-value consumables will be widely promoted in provinces and cities across the country in the coming years, the catalogue of centralized procurement will be continuously expanded, involving more products. Controlling fees and reducing prices and standardizing channels will be the general trend, and the industry concentration will continue to increase, In the future, leading enterprises with more innovative strength and willingness will accelerate their rise.
The company has provided better treatment solutions through continuous innovation of products and services, benefiting more than 6 million patients. Biosensors International Group, Ltd (hereinafter referred to as "Parkson international") is the world's fourth largest R & D, production and sales enterprise of cardiac stents, with a production capacity of 1426000 medical devices / year. Its subsidiary Shandong Jiwei Medical Products Co., Ltd. (hereinafter referred to as "Jiwei medical") is one of the three giants in the field of cardiac stents in China. Parkson international has its own patented drug biolimus a9tm. It has developed the world's first uncoated drug stent, biofreedomtm. It is the only drug stent approved by China's Drug Administration for high bleeding patients. Relying on the strong R & D strength of Parkson international, Jiwei medical launched the world's first biodegradable coated drug-eluting stent Exel ® (Excel), the new generation biodegradable coated drug-eluting stent Xinyue TM (excrossal), which won the first place in the national centralized procurement, and many other heavy-duty products, and will soon launch China's first molasses drug balloon product (ba9dcb, which was approved to enter the special review procedure of the State Drug Administration in August 2021). As a high-end Innovation Medical Management Co.Ltd(002173) device, TAVR has a promising market prospect. According to the calculation of Edwards Life Sciences, the global market scale of TAVR in 2018 was US $3.5 billion, and it is expected to reach US $7 billion in 2024. Although China's TAVR market is in the early stage of development, its scale is growing rapidly. The market scale of TAVR increased from 41 million yuan in 2017 to 556 million yuan in 2020, with a compound annual growth rate of 138.1%. At present, the implant products of TAVR in the world are still scarce. NVT has strong R & D strength in this field, and its core product Allegra ™ Obtained the EU CE in March 2017, and is the fifth TAVR manufacturer in the world to obtain the European CE registration; The indication of "valve in valve" was approved in Europe in May 2020. Even affected by the global covid-19 pneumonia epidemic, the sales volume of TAVR in the European market still returned to the pre epidemic level. Taking Spain as an example, the sales volume of TAVR in Spain has increased significantly. The compound annual growth rate of implant volume from 2018 to 2021 is still 10%, and the development trend is obvious.
Based on the strength of the cardiovascular department and its subsidiaries, the company has developed a strong strategy for the sustainable development of cardiovascular products. In particular, give full play to the innovative advantages of the company's independent research and development and global exclusive patented drug BA9, and independently develop differentiated and leading stents, balloons and other interventional medical devices carrying BA9 drugs through the leading technology of the combination of drugs and machinery, so as to create well-being for more patients. It has promoted the clinical and / or registration work of many projects such as drug coated balloon, interventional aortic valve and cobalt chromium alloy stent at home and abroad, is carrying out the research and development of new interventional devices such as total coronary calcification / CTO lesions and mitral valve repair / replacement, and has entered the track in the field of cardiovascular and cerebrovascular diseases such as structural heart disease and heart failure other than coronary intervention through investment extension, so as to continuously improve the company's competitive strength in the field of cardiovascular and cerebrovascular diseases Expand the leading edge.
③ Nursing department
According to the QY Research Report, in 2019, the global medical emergency kit market reached US $495 million, which is expected to reach US $744 million in 2026, and the compound growth rate (CAGR) from 2020 to 2026 is 5.90%. In 2019, the market scale of China's medical first aid kit reached 253 million US dollars, and it is expected to reach 401 million US dollars in 2026, with a compound annual growth rate of 6.62%. China is the world's largest exporter of medical first aid kits, and its products are exported to Europe, North America, Southeast Asia, the Middle East and other regions. In the downstream consumer market, medical first aid kits can be widely used in residential and office, vehicle, workshop, factory, military, outdoor and sports.
Wuhan bikele, a subsidiary of the company, has maintained the first export volume in China for five consecutive years. It is the second largest R & D and production enterprise of first-aid kits in the world and the first in Asia. It has formed long-term strategic cooperation with Tesla, German Mercedes Benz, BMW, Audi, French Renault and other automobile enterprises. The annual production capacity of first-aid kits exceeds 10 million sets, the annual production capacity of various masks exceeds 230 million, and the annual production capacity of reflective vests exceeds 4 million. Wuhan bikele continues to carry out internal lean production management, continuously improve production capacity, improve quality, optimize cost, save energy and reduce consumption, and improve enterprise production efficiency. In the field of first aid, the subsidiary Hubei Gaode first aid protective equipment Co., Ltd. closely follows the trends of the Chinese market and has developed eight series, including family emergency kit series, office first aid kit series, vehicle first aid kit series, travel first aid kit series, outdoor first aid kit series, health and epidemic prevention kit series, AED emergency kit series and training first aid kit series, with a total of 16 products. In 2021, the family emergency kit series and training first aid kit series were newly launched. Among them, the family emergency kit series was officially released at CMEF Shanghai Exhibition
